<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395705</url>
  </required_header>
  <id_info>
    <org_study_id>Henan CH</org_study_id>
    <nct_id>NCT02395705</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemotherapy Paclitaxel + Cisplatin Versus Surgery Alone for Stage IIA-IIIB Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of neo-adjuvant chemotherapy on survival of patients with thoracic esophageal
      squamous cell carcinomas remains the most controversial part of neo-adjuvant therapy for
      esophageal carcinomas. One of our objectives is to evaluate whether the neo-adjuvant therapy
      with cisplatin and paclitaxel followed by right thoracic approach esophagectomy with total
      2-field lymph node dissection improves the overall survival of thoracic esophageal cancer
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effect of Neo-adjuvant chemotherapy on survival of patients with thoracic esophageal
      squamous cell carcinomas remains the most controversial part of Neo-adjuvant therapy for
      esophageal carcinomas. Therefore, the optimal management of resectable esophageal squamous
      cell carcinomas differs widely among different areas based on local randomized controlled
      trials.

      The neo-adjuvant chemotherapy might be a good strategy if sufficient local control is
      achieved by surgical treatment. This study defined the detail of surgery procedure and the
      region of lymphadenectomy and adopted cisplatin and paclitaxel as neoadjuvant chemotherapy
      regimens. We try to evaluate the efficacy and safety of this neo-adjuvant strategy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>1 years and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Removal rate (R0 resection rate)</measure>
    <time_frame>perioperative period</time_frame>
    <description>The R0 resection rate of two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Rate of Operative Complication</measure>
    <time_frame>perioperative period</time_frame>
    <description>Complication rate after operation before discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Mortality of perioperation</measure>
    <time_frame>perioperative period</time_frame>
    <description>Mortality of perioperation 20 days before operation and 30 days after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Days of Hospitalization</measure>
    <time_frame>perioperative period</time_frame>
    <description>Days of Hospitalization after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Thoracic Drainage</measure>
    <time_frame>perioperative period</time_frame>
    <description>Thoracic Drainage days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Quantity of bleeding</measure>
    <time_frame>perioperative period</time_frame>
    <description>blood lose during operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment in perioperation-Time of operation</measure>
    <time_frame>perioperative period</time_frame>
    <description>the time from open thoracic cavity to the closure of the thoracic cavity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 years</time_frame>
    <description>ECOG, KPS, NRS-2002, EORTC QLQ-ST018, EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy of neo-adjuvant chemotherapy--response rate</measure>
    <time_frame>1-4 days before operation</time_frame>
    <description>Criteria:Response Evaluation Criteria in Solid Tumorsï¼ŒRECIST. Pathologic Complete Response Rate. Pathologic Response Rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicities of neo-adjuvant chemotherapy</measure>
    <time_frame>from chemotherapy to perioperative period</time_frame>
    <description>According to National Cancer Institute Common Terminology Criteria for Adverse Event,Version 3.0(CTC AE3.0). The complete rate of protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic factors</measure>
    <time_frame>5 years</time_frame>
    <description>prognostic factors for overall survival of both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictive factors</measure>
    <time_frame>2 years</time_frame>
    <description>predictive factors for the efficiency of neo-adjuvant chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">528</enrollment>
  <condition>Esophageal Neoplasm</condition>
  <arm_group>
    <arm_group_label>Neo-adjuvant chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neo-adjuvant chemotherapy(cisplatin and paclitaxel):
Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.
Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.
Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.
Surgery:
2-3weeks after Neo-adjuvant chemotherapy
Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.
Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery alone group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Surgery:
2-3weeks after Neo-adjuvant chemotherapy
Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.
Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin and paclitaxel</intervention_name>
    <description>Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.
Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.
Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.</description>
    <arm_group_label>Neo-adjuvant chemotherapy group</arm_group_label>
    <other_name>TP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologic diagnosis of squamous cell thoracic esophageal carcinoma of Stage IIA to
             IIIB, (7th Union for International Cancer Control, UICC-TNM).

          2. Patients must not have received any prior anticancer therapy of esophageal carcinoma.

          3. Age ranges from 18 to 75 years.

          4. Without operative contraindication.

          5. Absolute white blood cells count â‰¥4.0Ã—109/L, neutrophil â‰¥1.5Ã—109/L, platelets
             â‰¥100.0Ã—109/L, hemoglobin â‰¥90g/L, and normal functions of liver and kidney, total
             bilirubinï¼ˆTBILï¼‰â‰¤1.5N, aspartate aminotransferase (AST)â‰¤2.5N, alanine
             aminotransferase(ALT)â‰¤2.5N, prothrombin time(PT)â‰¤1.5N, and activated partial
             thromboplastin time(APTT) is in normal range, endogenous creatinine clearance
             rate(CRE)â‰¤1.5N.

          6. Patients must not have diagnosed with other cancer and must not received any prior
             anticancer therapy except prostatic cancer with more than 5 years disease-free
             survival(DFS).

          7. expected R0 resection.

          8. ECOG 0ï½ž2.

          9. Signed informed consent document on file. 10.No metastatic lymph node in cervical by
             color doppler sonography.

        Exclusion Criteria:

          1. Multiple primary cancer.

          2. The subject cannot understand and sign the informed consent form(ICF).

          3. Patients with concomitant hemorrhagic disease.

          4. Any un expected reason for patients can't get operation.

          5. Inability to use gastric conduit after esophagectomy because of a prior surgery.

          6. Pregnant or breast feeding.

          7. Patients are diagnosed or suspected to be allergic to cisplatin or Paclitaxel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yin Li, MD.&amp;PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yin Li, MD.&amp;PhD.</last_name>
    <phone>86-13903838752</phone>
    <email>liyin825@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Zheng, MD.&amp;PhD.</last_name>
    <phone>86-15713660065</phone>
    <email>sunnyzheng1@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousheng Mao, MD.</last_name>
      <email>maoysherx@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yousheng Mao, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keneng Chen, MD.</last_name>
      <email>chenkeneng@bjmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Keneng Chen, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>FuZhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun Chen, MD</last_name>
      <email>chenchun0209@163.com</email>
    </contact>
    <investigator>
      <last_name>Chun Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Uniersity Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Lin, MD &amp; PhD</last_name>
      <email>linpeng@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Peng Lin, MD &amp; PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anyang cancer hospital</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaobing Li, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xiaobing Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university</name>
      <address>
        <city>ZhengZhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin Li, M.D.&amp; Ph.D.</last_name>
      <phone>8613903838752</phone>
      <email>liyin825@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Yan Zheng, M.D.&amp; Ph.D.</last_name>
      <phone>8615713660065</phone>
      <email>sunnyzheng1@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yin Li, M.D.&amp; Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Province Tumor Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaoming Xiao, MD.</last_name>
      <email>xiaogaoming617@163.com</email>
    </contact>
    <investigator>
      <last_name>Gaoming Xiao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan Universitay Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiaqing Xiang, MD</last_name>
      <email>j.q.xiang@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jiaqing Xiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhentao Yu, MD.</last_name>
      <email>yuzhtao@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Zhentao Yu, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>July 9, 2017</last_update_submitted>
  <last_update_submitted_qc>July 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Yin Li</investigator_full_name>
    <investigator_title>Vice-President, Director of thoracic surgery department, Henan Cancer Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

